A randomized open-label study to investigate the impact of Bone Marker Feedback on adherence to monthly oral Bonviva [ibandronic acid] in women with postmenopausal osteoporosis.
Phase of Trial: Phase IV
Latest Information Update: 23 Feb 2010
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Biomarker; Therapeutic Use
- Acronyms BonAdAsia
- Sponsors Roche
- 18 Jun 2008 Status changed from recruiting to completed according to Roche Registry.
- 19 Jun 2006 New trial record.